Hutchison MediPharma Limited

Hutchison MediPharma Limited (HMPL) is a privately held biotechnology company engaged in the development of new drug Research and Development activities and drug discovery programs. Its R&D activities are focused on two therapeutic areas, namely, auto-immune/inflammatory disorders and oncology. Its product portfolio is in clinical stage of development which includes HMPL-004, a leading drug candidate for the treatment of inflammatory bowel disease and is in phase II stage; HMPL-011, a novel cytokine modulator for the treatment of variety of inflammatory disorders and is in phase II stage; HMPL-012, a novel VEGFR/FGFR inhibitor targeting tumor angiogenesis and is in pre-clinical stage of development; HMPL-013, a novel selective VEGFR inhibitor for treatment of cancer diseases and is in pre-clinical stage; HMPL-813, a potent EGFR kinase inhibitor for the treatment of variety of human tumors in xenograft models and is in pre-clinical stage of development. HMPL is headquartered at Shanghai, China.

Street: 
Building 4, 720 Cai Lun Road
City: 
Shanghai
Postcode: 
201203
Federal State : 
China
WebSite: 
www.hmplglobal.com
Fax: 
86-21-50793900

Company Index Score

Current Index Score Historical Index Score
  • Hutchison MediPharma Limited currently scores 50 % in the index.
  • Hutchison MediPharma Limited is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Hutchison MediPharma Limited is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets